Based on Fisher’s linear discriminant for relapse prediction, they identified cluster of differentiation 38 (CD38) as a potential marker for relapse, indicating that B-cells with low CD38 expression might serve as a potential indicator for relapse in ALL patients [64]. Here, CD38 is linked to acute lymphoblastic leukemia.